ClinicalTrials.Veeva

Menu

IMAGE-HF: Project IIa Canadian CArdiomyopathy Registry for Device Therapy (CanCARD-MR)

U

University of Ottawa Heart Institute

Status

Active, not recruiting

Conditions

Heart Failure

Study type

Observational

Funder types

Other

Identifiers

NCT04908306
2011308-01

Details and patient eligibility

About

Delayed enhanced MRI in patients (of either ischemic or non-ischemic cause) being referred for primary prevention ICD

Full description

Device therapy using defibrillators and cardiac resynchronization therapy (CRT) is an important advance in the care of patients with acquired heart disease and heart failure. In specific groups these devices appear to significantly reduce the risk of sudden cardiac death and progression of heart failure. However, our ability to identify ideal candidates, and those who are most likely to respond and benefit from this therapy, is poor.

Preliminary studies using specialized Magnetic Resonance Imaging (MRI) appears to be one of the more valuable ways of predicting response to device therapy and holds substantial promise for patients with cardiomyopathy.

Large, prospective registries are necessary to explore its real-world utility for risk prediction across a broad spectrum of patients. Can-CARD MR is a national, multi-centre registry designed to address this particular need.

Enrollment

502 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • .Any patient accepted for primary prevention ICD (+/-) CRT)

Exclusion criteria

  • Known contra-indications to MRI.
  • Recent myocardial infarction or revascularization procedure within the past 3 months.
  • GFR (glomerular filtration rate) ≤ 30 ml. / min/ m2.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems